Filtrer vos résultats
- 3
- 1
- 4
- 4
- 1
- 3
- 4
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Soluble CD163 and Incident Cardiovascular Events in Patients with Systemic Lupus Erythematosus: An Observational Cohort StudyJournal of Internal Medicine, 2022, 292 (3), pp.536--539. ⟨10.1111/joim.13490⟩
Article dans une revue
hal-03749906v1
|
||
|
Lack of Association between the TNFAIP3 Rs2230926 Variant and Rheumatoid Arthritis-Associated Lymphoma.Joint Bone Spine, 2022, 89 (5), pp.105390. ⟨10.1016/j.jbspin.2022.105390⟩
Article dans une revue
hal-03792023v1
|
||
|
Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter studyBlood, 2023, ⟨10.1182/blood.2022018665⟩
Article dans une revue
hal-04032447v1
|
||
|
Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study)Rheumatology, 2022, 61 (11), pp.4355-4363. ⟨10.1093/rheumatology/keac108⟩
Article dans une revue
hal-03856560v1
|